Pediatrix Medical Group (NYSE:MD) Price Target Raised to $18.00 at Jefferies Financial Group

Pediatrix Medical Group (NYSE:MD) had its target price hoisted by investment analysts at Jefferies Financial Group from $14.00 to $18.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective points to a potential upside of 18.89% from the stock’s previous close.

A number of other research firms have also recently weighed in on MD. UBS Group upped their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research report on Friday, August 9th. StockNews.com upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft lifted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday. Truist Financial increased their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday. Finally, Mizuho boosted their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Monday. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $14.90.

Pediatrix Medical Group Stock Performance

MD opened at $15.14 on Tuesday. The firm has a fifty day moving average price of $11.70 and a 200 day moving average price of $9.45. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $15.43. The stock has a market cap of $1.30 billion, a P/E ratio of -4.95, a P/E/G ratio of 2.36 and a beta of 1.55. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.58 and a quick ratio of 1.38.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. During the same quarter in the previous year, the company earned $0.29 earnings per share. The firm’s revenue for the quarter was up .9% on a year-over-year basis. Equities research analysts anticipate that Pediatrix Medical Group will post 1.19 earnings per share for the current year.

Insider Transactions at Pediatrix Medical Group

In related news, CFO C Marc Richards sold 17,438 shares of Pediatrix Medical Group stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $10.08, for a total transaction of $175,775.04. Following the transaction, the chief financial officer now owns 175,347 shares in the company, valued at approximately $1,767,497.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the sale, the director now owns 30,805 shares of the company’s stock, valued at $343,783.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO C Marc Richards sold 17,438 shares of Pediatrix Medical Group stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $10.08, for a total transaction of $175,775.04. Following the sale, the chief financial officer now directly owns 175,347 shares in the company, valued at approximately $1,767,497.76. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 68,100 shares of company stock worth $701,889 in the last ninety days. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company grew its holdings in shares of Pediatrix Medical Group by 3.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company’s stock worth $245,000 after purchasing an additional 1,088 shares during the period. ProShare Advisors LLC boosted its position in shares of Pediatrix Medical Group by 7.4% during the 1st quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock worth $170,000 after purchasing an additional 1,167 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Pediatrix Medical Group by 47.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after purchasing an additional 1,524 shares during the period. SummerHaven Investment Management LLC increased its holdings in Pediatrix Medical Group by 3.8% in the 2nd quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company’s stock valued at $422,000 after purchasing an additional 2,069 shares during the last quarter. Finally, Bank of Montreal Can raised its position in Pediatrix Medical Group by 0.5% in the second quarter. Bank of Montreal Can now owns 415,110 shares of the company’s stock valued at $3,196,000 after purchasing an additional 2,083 shares during the period. Hedge funds and other institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.